NEURO61

Session information

[held on paper]Oral Session

[O-29] Oral Session 29
Neuroimmunology 3 E

Hiroshi Kuroda1,2, Kimihiko Kaneko1, Takaaki Nakamura1, Yoshiki Takai1, Shuhei Nishiyama1, Tatsuro Misu1, Kazuo Fujihara1,3,4, Masashi Aoki1 (1.Department of Neurology, Tohoku University Graduate School of Medicine, Japan, 2.Department of Neurology, South Miyagi Medical Center, Japan, 3.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, 4.Department of Multiple Sclerosis Therapeutics, Southern TOHOKU Research Institute for Neuroscience)

Akihiro Mukaino1,2, Shunya Nakane1,2, Osamu Higuchi3, Yasuhiro Maeda3, Makoto Yamakawa2, Kotaro Takamatsu2, Hidenori Matsuo3 (1.Department of Molecular Neurology and Therapeutics, Kumamoto University Hospital, Japan, 2.Department of Neurology, Kumamoto University, Japan, 3.Department of Clinical Research and Neurology, Nagasaki Kawatana Medical Center, Japan)

Kazuo Fujihara1, Benjamin Greenberg2, Jerome De Seze3, Edward Fox4, Albert Saiz5, Takashi Yamamura6, Carole Marcillat7, Xiujing Kou7, Kristina Weber7, Brian G. Weinshenker8 (1.Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, Japan, 2.University of Texas Southwestern Medical Center, 3.Department of Neurology, Hôpital de Hautepierre INSERM, 4.Central Texas Neurology Consultants, 5.Service of Neurology, University of Barcelona, 6.National Institute of Neuroscience, National Center of Neurology and Psychiatry, 7.F. Hoffmann-La Roche Ltd, 8.Department of Neurology, Mayo Clinic)